254 related articles for article (PubMed ID: 19486119)
1. The effects of antihypertensive treatment on the doppler-derived myocardial performance index in patients with hypertensive left ventricular hypertrophy: results from the Swedish irbesartan in left ventricular hypertrophy investigation versus atenolol (SILVHIA).
Liljedahl S; Kahan T; Lind L; Arnlöv J
Echocardiography; 2009 Aug; 26(7):753-8. PubMed ID: 19486119
[TBL] [Abstract][Full Text] [Related]
2. Tissue velocity echocardiography shows early improvement in diastolic function with irbesartan and atenolol therapy in patients with hypertensive left ventricular hypertrophy. Results form the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA).
Müller-Brunotte R; Kahan T; Malmqvist K; Ring M; Edner M
Am J Hypertens; 2006 Sep; 19(9):927-36. PubMed ID: 16942935
[TBL] [Abstract][Full Text] [Related]
3. Irbesartan reduces common carotid artery intima-media thickness in hypertensive patients when compared with atenolol: the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) study.
Mörtsell D; Malmqvist K; Held C; Kahan T
J Intern Med; 2007 May; 261(5):472-9. PubMed ID: 17444886
[TBL] [Abstract][Full Text] [Related]
4. Comparison of actions of irbesartan versus atenolol on cardiac repolarization in hypertensive left ventricular hypertrophy: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation Versus Atenolol (SILVHIA).
Malmqvist K; Kahan T; Edner M; Bergfeldt L
Am J Cardiol; 2002 Nov; 90(10):1107-12. PubMed ID: 12423712
[TBL] [Abstract][Full Text] [Related]
5. Myocardial fibrosis and diastolic dysfunction in patients with hypertension: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA).
Müller-Brunotte R; Kahan T; López B; Edner M; González A; Díez J; Malmqvist K
J Hypertens; 2007 Sep; 25(9):1958-66. PubMed ID: 17762662
[TBL] [Abstract][Full Text] [Related]
6. Nurse-recorded and ambulatory blood pressure predicts treatment-induced reduction of left ventricular hypertrophy equally well in hypertension: results from the Swedish irbesartan left ventricular hypertrophy investigation versus atenolol (SILVHIA) study.
Nyström F; Malmqvist K; Ohman KP; Kahan T
J Hypertens; 2002 Aug; 20(8):1527-33. PubMed ID: 12172314
[TBL] [Abstract][Full Text] [Related]
7. The relationship between the plasma concentration of irbesartan and the antihypertensive response is disclosed by an angiotensin II type 1 receptor polymorphism: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs. Atenolol (SILVHIA) Trial.
Kurland L; Hallberg P; Melhus H; Liljedahl U; Hashemi N; Syvänen AC; Lind L; Kahan T
Am J Hypertens; 2008 Jul; 21(7):836-9. PubMed ID: 18464745
[TBL] [Abstract][Full Text] [Related]
8. Transforming growth factor beta1 genotype and change in left ventricular mass during antihypertensive treatment--results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA).
Hallberg P; Lind L; Billberger K; Michaelsson K; Karlsson J; Kurland L; Kahan T; Malmqvist K; Ohman KP; Nyström F; Liljedahl U; Syvänen AC; Melhus H
Clin Cardiol; 2004 Mar; 27(3):169-73. PubMed ID: 15049387
[TBL] [Abstract][Full Text] [Related]
9. Regression of left ventricular hypertrophy in human hypertension with irbesartan.
Malmqvist K; Kahan T; Edner M; Held C; Hägg A; Lind L; Müller-Brunotte R; Nyström F; Ohman KP; Osbakken MD; Ostergern J
J Hypertens; 2001 Jun; 19(6):1167-76. PubMed ID: 11403367
[TBL] [Abstract][Full Text] [Related]
10. Polymorphisms in the angiotensinogen and angiotensin II type 1 receptor gene are related to change in left ventricular mass during antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial.
Kurland L; Melhus H; Karlsson J; Kahan T; Malmqvist K; Ohman P; Nyström F; Hägg A; Lind L
J Hypertens; 2002 Apr; 20(4):657-63. PubMed ID: 11910301
[TBL] [Abstract][Full Text] [Related]
11. B2 bradykinin receptor (B2BKR) polymorphism and change in left ventricular mass in response to antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial.
Hallberg P; Lind L; Michaëlsson K; Karlsson J; Kurland L; Kahan T; Malmqvist K; Ohman KP; Nyström F; Melhus H
J Hypertens; 2003 Mar; 21(3):621-4. PubMed ID: 12640257
[TBL] [Abstract][Full Text] [Related]
12. Gender-specific association between preproendothelin-1 genotype and reduction of systolic blood pressure during antihypertensive treatment--results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA).
Hallberg P; Karlsson J; Lind L; Michaëlsson K; Kurland L; Kahan T; Malmqvist K; Ohman KP; Nyström F; Liljedahl U; Syvänen AC; Melhus H
Clin Cardiol; 2004 May; 27(5):287-90. PubMed ID: 15188945
[TBL] [Abstract][Full Text] [Related]
13. Long-term effects of irbesartan and atenolol on the renin-angiotensin-aldosterone system in human primary hypertension: the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA).
Malmqvist K; Ohman KP; Lind L; Nyström F; Kahan T
J Cardiovasc Pharmacol; 2003 Dec; 42(6):719-26. PubMed ID: 14639093
[TBL] [Abstract][Full Text] [Related]
14. Irbesartan and atenolol improve diastolic function in patients with hypertensive left ventricular hypertrophy.
Müller-Brunotte R; Edner M; Malmqvist K; Kahan T
J Hypertens; 2005 Mar; 23(3):633-40. PubMed ID: 15716707
[TBL] [Abstract][Full Text] [Related]
15. Aldosterone synthase (CYP11B2) -344 C/T polymorphism is related to antihypertensive response: result from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial.
Kurland L; Melhus H; Karlsson J; Kahan T; Malmqvist K; Ohman P; Nyström F; Hägg A; Lind L
Am J Hypertens; 2002 May; 15(5):389-93. PubMed ID: 12022239
[TBL] [Abstract][Full Text] [Related]
16. The CYP2C9 genotype predicts the blood pressure response to irbesartan: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial.
Hallberg P; Karlsson J; Kurland L; Lind L; Kahan T; Malmqvist K; Ohman KP; Nyström F; Melhus H
J Hypertens; 2002 Oct; 20(10):2089-93. PubMed ID: 12359989
[TBL] [Abstract][Full Text] [Related]
17. Treatment of diastolic dysfunction in hypertensive left ventricular hypertrophy.
Bella JN
Am J Hypertens; 2006 Sep; 19(9):937-8. PubMed ID: 16942936
[No Abstract] [Full Text] [Related]
18. Angiotensinogen gene polymorphisms: relationship to blood pressure response to antihypertensive treatment. Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial.
Kurland L; Liljedahl U; Karlsson J; Kahan T; Malmqvist K; Melhus H; Syvänen AC; Lind L
Am J Hypertens; 2004 Jan; 17(1):8-13. PubMed ID: 14700505
[TBL] [Abstract][Full Text] [Related]
19. Cardiac repolarization and its relation to ventricular geometry and rate in reverse remodelling during antihypertensive therapy with irbesartan or atenolol: results from the SILVHIA study.
Malmqvist K; Kahan T; Edner M; Bergfeldt L
J Hum Hypertens; 2007 Dec; 21(12):956-65. PubMed ID: 17637792
[TBL] [Abstract][Full Text] [Related]
20. Markers of inflammation, endothelial activation, and arterial stiffness in hypertensive heart disease and the effects of treatment: results from the SILVHIA study.
Jekell A; Malmqvist K; Wallén NH; Mörtsell D; Kahan T
J Cardiovasc Pharmacol; 2013 Dec; 62(6):559-66. PubMed ID: 24084214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
